<DOC>
	<DOCNO>NCT02342093</DOCNO>
	<brief_summary>Background : Drospirenone ( DRSP ) seem favorable effect blood pressure ( BP ) ; however , associate ethinylestradiol ( EE ) , effect seem occur . This study objective ass possible difference BP associate use COCs contain DRSP different dos ethinylestradiol . Materials method : This open-label parallel-group randomize clinical trial involve woman randomize use either 30 mcg EE+DRSP ( n=22 ) 20 mcg EE+DRSP ( n=22 ) . Daytime , nighttime 24-hour BP evaluate ambulatory blood pressure monitoring ( ABPM ) begin trial six month drug therapy .</brief_summary>
	<brief_title>Contraceptives Containing Drospirenone Blood Pressure</brief_title>
	<detailed_description />
	<mesh_term>Drospirenone</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>sexually active woman wish become pregnant , age 18 35 , menstrual cycle last 24 32 day , body mass index ( BMI ) 18.0 29.9 kg/m2 smoking , use drug and/or alcohol , clinical and/or laboratory sign hyperandrogenism , use hormonal contraception within six month initiation study , presence chronic and/or acute inflammatory process , use medication endothelial effect ( e.g. , statin ) , breastfeed stop breastfeed within two month initiation study , medical condition classify category 3 4 accord WHO medical eligibility criterion contraceptive prescription</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Ambulatory Blood Pressure Monitoring</keyword>
	<keyword>Drospirenone</keyword>
	<keyword>Oral contraceptive</keyword>
</DOC>